Invesco Energy Exploration & Production ETF(PXE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PXE Invesco Energy Exploration & Production ETF

Pre-Market Trading 11-26 08:59:28 EST

32.27

-0.43

-1.31%

盘前32.00

-0.27-0.84%

08:12 EST

High32.84	Low32.27	Vol211.97K
Open32.74	D1 Closing32.70	Amplitude1.74%
Mkt Cap120.37M	Tradable Cap120.37M	Total Shares3.73M
T/O6.87M	T/O Rate5.68%	Tradable Shares3.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PXE","market":"US","secType":"STK","nameCN":"Invesco Energy Exploration & Production ETF","latestPrice":32.2707,"timestamp":1732568400000,"preClose":32.7001,"halted":0,"volume":211971,"hourTrading":{"tag":"盘前","latestPrice":32,"preClose":32.2707,"latestTime":"08:12 EST","volume":5,"amount":160.57,"timestamp":1732626735636},"delay":0,"floatShares":3730000,"shares":3730000,"eps":8.929016,"marketStatus":"Pre-Market Trading","change":-0.4294,"latestTime":"11-26 08:59:28 EST","open":32.74,"high":32.8388,"low":32.27,"amount":6865637.884065,"amplitude":0.017394,"askPrice":35.7,"askSize":100,"bidPrice":29.3,"bidSize":100,"shortable":3,"etf":1,"ttmEps":8.929016,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732631400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":32.2707,"sharesOutstanding":3730000,"nav":32.70327,"aum":121983197.1,"dividendRate":0.026652,"bidAskSpread":0.000678,"preHourTrading":{"tag":"盘前","latestPrice":32,"preClose":32.2707,"latestTime":"08:12 EST","volume":5,"amount":160.57,"timestamp":1732626735636},"postHourTrading":{"tag":"盘后","latestPrice":32.2707,"preClose":32.2707,"latestTime":"17:11 EST","volume":2,"amount":65.92,"timestamp":1732572712167},"volumeRatio":7.15455965959035,"impliedVol":0.0565,"impliedVolPercentile":0.0635},"requestUrl":"/m/hq/s/PXE/tweets","defaultTab":"tweets","newsList":[{"id":"2481950195","title":"Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481950195","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481950195?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813400,"startTime":"0","endTime":"0","summary":"- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –。- Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 -. - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding -. BOSTON, Nov. 05, 2024  -- Inozyme Pharma, Inc. , a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.Phase 1 Trial of INZ-701 in Patients with End-Stage Kidney Disease  Undergoing Hemodialysis. In October 2024, the Company announced positi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TtfUSRcXuiiTrUF2RvpvvQ--~B/aD0yNTI7dz05MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3bb9ff2ad714f6f291f9fd0b6a76f48b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TtfUSRcXuiiTrUF2RvpvvQ--~B/aD0yNTI7dz05MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3bb9ff2ad714f6f291f9fd0b6a76f48b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inozyme-pharma-reports-third-quarter-133000375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INZY","BK4139","PXE"],"gpt_icon":0},{"id":"2477632599","title":"Valero Energy Delivers Solid Q3: Ethanol, Renewable Diesel Volumes Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2477632599","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477632599?lang=en_us&edition=fundamental","pubTime":"2024-10-24 22:02","pubTimestamp":1729778557,"startTime":"0","endTime":"0","summary":"Valero Energy Corporation (NYSE: VLO) reported Q3 FY24 revenues of $32.876B, beating consensus. Adj. EPS exceeded consensus. Refining segment income down.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41519242/valero-energy-delivers-solid-q3-ethanol-renewable-diesel-volumes-rise","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4138","LU0122376428.USD","LU0345780950.USD","SG9999001440.SGD","VLO","PXE","IE00B2Q91V27.USD","LU0345781412.USD","LU0456854461.SGD","BK4585","IE00BGHQF524.EUR","LU0266512127.USD","IE00B3CCJ963.GBP","IE00BSNM7G36.USD","LU0300736492.USD","BK4588","LU0630314457.HKD","LU0368265418.SGD","CRAK","LU0788109394.HKD"],"gpt_icon":0},{"id":"2470780340","title":"Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2470780340","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470780340?lang=en_us&edition=fundamental","pubTime":"2024-09-26 20:00","pubTimestamp":1727352000,"startTime":"0","endTime":"0","summary":"- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children - - Inozyme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/26/2953744/0/en/Inozyme-Pharma-Presents-New-Data-at-the-American-Society-for-Bone-and-Mineral-Research-ASBMR-2024-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","PXE","INZY","BK4107","BK4139","AFG"],"gpt_icon":0},{"id":"2466727743","title":"Inozyme draws buy at Stifel on lead asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2466727743","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466727743?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:33","pubTimestamp":1726144413,"startTime":"0","endTime":"0","summary":"Inozyme Pharma  traded higher in the premarket on Thursday after Stifel launched its coverage with a buy recommendation arguing that its lead asset, INZ-701, has the potential to become a pipeline-in-a-product. INZ-701 is an enzyme replacement therapy targeted at a trio of rare disorders, ENPP1 deficiency, calciphylaxis, and pseudoxanthoma elasticum , caused by deficiencies of inorganic pyrophosphate , a regulator of cellular function. \"Although lead indications are rare, we believe INZ-70 has a pipeline-in-a-product potential that a seasoned management team can extract maximal value from,\" Stifel analyst Dae Gon Ha wrote with a $16 price target on the stock. The analyst added that by year-end, Phase 1 interim data for INZ-70 from the SEAPORT 1 trial for calciphylaxis and the ENERGY 1 trial in infants with ENPP1 deficiency \"have a chance to instill investor confidence prior to additional catalysts in 2025. \"","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185078746/image_185078746.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185078746/image_185078746.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4148980-inozyme-stock-draws-buy-stifel-lead-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["INZY","PXE","BK4139","BK4127","SF"],"gpt_icon":0},{"id":"2460716074","title":"Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2460716074","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460716074?lang=en_us&edition=fundamental","pubTime":"2024-08-18 21:03","pubTimestamp":1723986216,"startTime":"0","endTime":"0","summary":"While inflation has eased to 2.9% in July, interest rates remain elevated, with the Federal Reserve’s key rate currently at 5.25% to 5.50%. However, it is widely expected that the Fed will begin cutting rates as early as next month.A reduction in rates is likely to send ripples across various sectors, with the biotech industry being particularly affected. Biotech companies, which often operate with significant overhead costs, are especially sensitive to changes in interest rates. But with a rate cut likely in the offing, market dynamics for biotech could see a favorable shift in the coming months.INZ-701 is also being developed to treat ABCC6 deficie","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gYzBAjec3Dy_VGdZDEqFaw--~B/aD01NDg7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/bb8dec60d17464481de3a5da8852aae9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gYzBAjec3Dy_VGdZDEqFaw--~B/aD01NDg7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/bb8dec60d17464481de3a5da8852aae9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jefferies-predicts-270-rally-2-130336324.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jefferies-predicts-270-rally-2-130336324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INZY","TNGX","PXE"],"gpt_icon":0},{"id":"2459139370","title":"Inozyme draws Buy at Jefferies on rare disease opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2459139370","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459139370?lang=en_us&edition=fundamental","pubTime":"2024-08-14 03:28","pubTimestamp":1723577294,"startTime":"0","endTime":"0","summary":"Inozyme Pharma  traded higher on Tuesday after Jefferies assumed its coverage with a Buy rating and a $17 price target, citing three rare disease opportunities for the company’s lead asset, INZ-701. The enzyme replacement therapy is currently undergoing clinical studies for ENPP1 deficiency, calciphylaxis, and pseudoxanthoma elasticum , a trio of rare disorders caused by deficiencies of inorganic pyrophosphate , a regulator of cellular function.  Jefferies analyst Maury Raycroft said INZ-701, designed to increase PPi, can achieve $2.5B in peak revenue. The experimental therapy can potentially increase PPi to normal levels in these disease areas, according to the analyst. Additionally, Raycroft underscored upcoming catalysts for INZ-701, including a Phase 1 readout in calciphylaxis and a topline readout from a pediatric pivotal trial for ENPP1 deficiency scheduled for Q4 and H2 2025, respectively.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1439138405/image_1439138405.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1439138405/image_1439138405.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4139385-inozyme-stock-draws-buy-jefferies","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["INZY","PXE","BK4139"],"gpt_icon":0},{"id":"2457419410","title":"Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2457419410","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457419410?lang=en_us&edition=fundamental","pubTime":"2024-08-06 20:30","pubTimestamp":1722947400,"startTime":"0","endTime":"0","summary":"- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/06/2925066/0/en/Inozyme-Pharma-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENDO","PXE","INZY","BK4183"],"gpt_icon":0},{"id":"2448546613","title":"XES: A Tactical Hold With Bullish Potential In The Oil And Gas Services Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2448546613","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448546613?lang=en_us&edition=fundamental","pubTime":"2024-07-04 09:11","pubTimestamp":1720055496,"startTime":"0","endTime":"0","summary":"XES offers exposure to oil and gas services sector with modified equal-weighted index approach and low expense ratio.XES lags in dividend performance compared to peers, but offers strong liquidity and","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1447640636/image_1447640636.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1447640636/image_1447640636.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4702353-xes-a-tactical-hold-with-bullish-potential-in-the-oil-and-gas-services-sector","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4159","XES","TTM","IEO","BK4588","BK4523","BK4585","BK4550","BK4099","FDN","CAGR","PXE"],"gpt_icon":0},{"id":"2448155003","title":"Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2448155003","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448155003?lang=en_us&edition=fundamental","pubTime":"2024-07-02 20:30","pubTimestamp":1719923400,"startTime":"0","endTime":"0","summary":"Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 DeficiencyBOSTON, July  02, 2024  (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/02/2907394/0/en/Inozyme-Pharma-Announces-FDA-Fast-Track-Designation-for-INZ-701-in-ABCC6-Deficiency.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FAST","PXE","INZY"],"gpt_icon":0},{"id":"2440689910","title":"PXE: Investing In Oil And Gas Depends On Your Time Horizon","url":"https://stock-news.laohu8.com/highlight/detail?id=2440689910","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2440689910?lang=en_us&edition=fundamental","pubTime":"2024-06-01 00:45","pubTimestamp":1717173940,"startTime":"0","endTime":"0","summary":"chekyfoto Investment Thesis Invesco Energy Exploration & Production ETF (NYSEARCA:PXE) is a hold due to mixed factors impacting investment in the oil and gas industry. While crude oil and natural gas ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298570727/image_1298570727.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298570727/image_1298570727.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4696784-pxe-investing-in-oil-and-gas-depends-on-your-time-horizon","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["LU0300736062.USD","LU0256331488.USD","LU0320765646.SGD","FANG.AU","LU1732799900.SGD","LU1732800096.USD","FANG","LU0433182093.SGD","LU1839511570.USD","SG9999014559.SGD","IE00B1XK9C88.USD","FDN","LU1066053197.SGD","FCG","LU0795875169.SGD","LU0466842654.USD","LU1150488135.SGD","LU0266512127.USD","IE00BKDWB100.SGD","BK4138","SG9999014567.USD","FCG.AU","LU1066051498.USD","TTTN","LU0878866978.SGD","BK4534","BK4516","LU2087621335.USD","CTRA","IEO","LU1150488218.USD","XLE","LU0122376428.USD","VLO","BK4550","XOM","BK4570","LU1074936037.SGD","BK7124","BK4201","XOP","LU0068578508.USD","LU0985489474.SGD","SG9999014575.USD","LU0792757196.USD","LU0889566641.SGD","BK4585","SG9999015358.SGD","PXE","SG9999015341.SGD"],"gpt_icon":0},{"id":"2437569487","title":"Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2437569487","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2437569487?lang=en_us&edition=fundamental","pubTime":"2024-05-23 20:30","pubTimestamp":1716467400,"startTime":"0","endTime":"0","summary":"BOSTON, May  23, 2024  (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.(Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/23/2887263/0/en/Inozyme-Pharma-to-Present-Recently-Announced-Data-from-Phase-1-2-Trials-of-INZ-701-in-Adults-with-ENPP1-Deficiency-and-ABCC6-Deficiency-PXE-at-Upcoming-Medical-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","PD","BK4023","BK4183","BK4218","ENDO","BK4139","BK4181","PK","PXE","LU1169589451.USD","INZY"],"gpt_icon":0},{"id":"2435542451","title":"19 Stocks and ETFs to benefit from the electrification theme and future energy technologies - BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2435542451","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435542451?lang=en_us&edition=fundamental","pubTime":"2024-05-15 03:00","pubTimestamp":1715713202,"startTime":"0","endTime":"0","summary":"BofA Securities analysts listed 19 investable options to gain exposure to the electrification theme of future technology. According to BofA’s RIC Report, manufacturing, data centers, artificial intell","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1252617520/image_1252617520.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1252617520/image_1252617520.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105948-19-stocks-and-etfs-to-benefit-from-the-electrification-theme-and-future-energy-technologies-bofa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ETN","PEG","CCJ","LU0234572021.USD","BK7084","KMI","LU0444971666.USD","CCJ.AU","GEV.AU","LU1093756325.SGD","IE00BD6J9T35.USD","BK4561","NVDA","ET","LU1992135399.USD","VRT","XEL","IE00B19Z3B42.SGD","LU0061475181.USD","FDN","LU0234570918.USD","GEV","LU1023059493.AUD","LU0708994859.HKD","LU1992135472.HKD","PNW","BHP.AU","ETR.AU","LU2637428348.USD","VRT.AU","BK4527","LU2237438978.USD","CAT.AU","OIH","LU0353189763.USD","PXE","IE0004445239.USD","LU0053666078.USD","LU0300736492.USD","CAT","AZPN","XLK","BHP","LU1093756168.USD","LU1861214812.USD","WMB","ETR","IE0002270589.USD","LU0310800379.SGD","FCX"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0746},{"period":"3month","weight":0.0183},{"period":"6month","weight":-0.0402},{"period":"1year","weight":0.0287},{"period":"ytd","weight":0.0444}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund invests at least 90% of its total assets in securities that comprise the underlying index. The index was composed of common stocks of U.S. companies involved in the exploration and production of natural resources used to produce energy. These companies are engaged principally in exploration, extraction and production of crude oil and natural gas from land-based or offshore wells. The fund is non-diversified.","yearOnYearQuotes":[{"month":1,"riseRate":0.473684,"avgChangeRate":0.014652},{"month":2,"riseRate":0.526316,"avgChangeRate":-0.003915},{"month":3,"riseRate":0.684211,"avgChangeRate":0.018416},{"month":4,"riseRate":0.736842,"avgChangeRate":0.069826},{"month":5,"riseRate":0.421053,"avgChangeRate":0.003959},{"month":6,"riseRate":0.421053,"avgChangeRate":-0.006874},{"month":7,"riseRate":0.578947,"avgChangeRate":-0.001265},{"month":8,"riseRate":0.421053,"avgChangeRate":-0.011132},{"month":9,"riseRate":0.526316,"avgChangeRate":-0.016948},{"month":10,"riseRate":0.473684,"avgChangeRate":0.017444},{"month":11,"riseRate":0.45,"avgChangeRate":0.017985},{"month":12,"riseRate":0.473684,"avgChangeRate":-0.001822}],"exchange":"ARCA","name":"Invesco Energy Exploration & Production ETF","nameEN":"Invesco Energy Exploration & Production ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Invesco Energy Exploration & Production ETF(PXE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Invesco Energy Exploration & Production ETF(PXE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Invesco Energy Exploration & Production ETF,PXE,Invesco Energy Exploration & Production ETF股票,Invesco Energy Exploration & Production ETF股票老虎,Invesco Energy Exploration & Production ETF股票老虎国际,Invesco Energy Exploration & Production ETF行情,Invesco Energy Exploration & Production ETF股票行情,Invesco Energy Exploration & Production ETF股价,Invesco Energy Exploration & Production ETF股市,Invesco Energy Exploration & Production ETF股票价格,Invesco Energy Exploration & Production ETF股票交易,Invesco Energy Exploration & Production ETF股票购买,Invesco Energy Exploration & Production ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Invesco Energy Exploration & Production ETF(PXE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Invesco Energy Exploration & Production ETF(PXE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction